This week marks the first Monday in October, which for Supreme Court watchers is a holiday: the start of a new term. While not everyone gets that excited about the new term, there are several cases that the Court intends to hear this term that merit attention from businesses in the automotive sector. Below is a quick look at five cases that inside counsel in the industry should keep an eye on:
- NLRB v. Noel Canning, No. 12-1281. While the issues presented seem to raise esoteric issues of constitutional law—can the President make recess appointments to a government agency while Congress is in session but on recess; and can the President make a recess appointment to fill a vacancy when the vacancy first arose while Congress was in session—the implications are far-reaching. As covered by this blog when the Third Circuit ruled upon the issue, and elsewhere when the Noel Canning case was decided by the D.C. Circuit, the Supreme Court’s answer could determine whether any quasi-judicial actions taken by the Board of the NLRB (which requires a quorum of three out of five to hear administrative cases) between March 2010 and July 2013 are valid. Beyond determining whether Board actions taken over the period of over three years are valid, Noel Canning will shed light on whether the Senate can, by denying its consent to the President’s appointments, effectively shut down the quasi-judicial activities of agencies like the NLRB. A hearing date has not been set.
- DaimerChrysler AG v. Bauman, No. 11-965. Covered in more detail here, this case asks whether a court can exercise jurisdiction over a foreign corporation on the basis that one of its subsidiaries operated in the same state as the court. The case arises from allegations of human rights abuses by Mercedes-Benz Argentina, a subsidiary of DaimlerChrysler AG’s predecessor (DaimlerChrysler AG is itself now simply Daimler AG), and plaintiffs asserted jurisdiction over DaimlerChrysler AG based on the presence of another subsidiary (Mercedes-Benz USA, LLC) in California. The Ninth Circuit agreed with plaintiffs. The Supreme Court’s decision will clarify the degree to which multinational corporations can compartmentalize risks arising in one country through the use of parent-subsidiary structures. The case is scheduled to be heard on October 15.
- Medtronic, Inc. v. Boston Scientific Corp., No. 12-1128. In 2007, the Supreme Court held in MedImmune, Inc. v. Genentech, Inc. that a patent licensee being asked to pay royalties on a product could file a declaratory judgment action to clarify whether the licensee’s product was covered by the licensor’s patent, rather than being required to refuse to pay and wait to be sued for breach of the license agreement. A question that has arisen is who has the burden of proof with regard to proving or disproving infringement in such a suit. Where the licensor files suit for patent infringement, it is generally the licensor’s burden to prove infringement; nonetheless, in Medtronic, the Federal Circuit held that it was the licensee’s burden to disprove infringement when a declaratory judgment suit was filed under MedImmune, making the declaratory judgment mechanism much less attractive to a licensee accused of infringement. The Supreme Court has granted review, and will likely decide whether the Federal Circuit is right, or whether the licensor has the burden to prove infringement when sued by a licensee seeking a declaratory judgment. The case is scheduled to be heard on November 5, 2013.
- Lexmark Int’l, Inc. v. Static Control Components, Inc., No. 12-873. The Lanham Act provides, among other things, an action for false advertising. However, it is unclear who may sue for false advertising under the Lanham Act: some courts only permit a direct competitor to sue for false advertising; other courts weigh a series of factors based mostly on how directly the plaintiff is injured by the false advertising; and some courts simply ask if there is a reasonable interest to be protected and a reasonable basis for believing that interest would be harmed by the claimed false advertisement. The Supreme Court’s decision should clarify which of these tests—or if another test entirely—applies to who may sue for false advertising under the Lanham Act. The answer will determine both the availability of a false advertisement claim for businesses looking to protect their interests, and, conversely, the potential exposure of businesses to false advertising actions brought by plaintiffs that are not direct competitors. The case is scheduled for argument on December 3, 2013.
- Unite Here Local 355 v. Mulhall, No. 12-99. The Labor-Management Relations Act makes it a crime for an employer “to pay, lend, or deliver, or agree to pay, lend, or deliver any money or other thing of value” to, among other things, a “labor organization . . . which represents, or seeks to represent,” any of that employer’s employees. Unite Here and Mardi Gras Gaming entered into a Memorandum of Understanding that provided that Mardi Gras Gaming—the employer—would: provide Unite Here with information about employees; provide Unite Here with use of the employer’s property for organizing; and refrain from making any statements opposing unionization. The question presented is whether such an agreement to assist organization, in return for guarantees of labor peace, violated the Labor-Management Relations Act. Two federal appellate courts considering similar agreements have said no, this case comes to the Supreme Court from a court that said yes. The answer may determine the flexibility of unions and employers to contract with one another in a manner that promises assistance in unionization in return for a more harmonious relationship between the union and the employer, which could become more important as unions reassert their presence in the auto industry. The case is scheduled for argument on November 13, 2013.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Related Insights
23 December 2024
Labor & Employment Law Perspectives
Regulating Artificial Intelligence in Employment Decision-Making: What’s on the Horizon for 2025
Share on TwitterShare by EmailShareBack to topEmployment law in 2024 could aptly be summarized as the “Year of Artificial Intelligence Legislation.
23 December 2024
Health Care Law Today
Medicare Telehealth Flexibilities Get a Three-Month Lifeline
Share on TwitterShare by EmailShareBack to topAfter much uncertainty, Congress has extended many Medicare telehealth flexibilities through March 31, 2025, in its end-of-year appropriations bill.
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.